Redirecting to https://markets.businessinsider.com/news/stocks/arrivent-to-present-two-preclinical-posters-on-the-egfr-inhibitor-firmonertinib-and-on-the-novel-dual-target-muc16-napi2b-tetravalent-adc-arr-002-at-the-2026-aacr-annual-meeting-1035938979